PHARMACOKINETICS OF GANCICLOVIR IN RENAL-TRANSPLANT CHILDREN

被引：11

作者：

JACQZAIGRAIN, E

MACHER, MA

SAUVAGEONMARTHE, H

BRUN, P

LOIRAT, C

机构：

[1] Department of Clinical Pharmacology, Hôpital Robert-Debré, Paris Cédex 19, F-75935

[2] Department of Nephrology, Hôpital Robert-Debré, Paris Cédex 19, F-75935

[3] Service de Pharmacologie, Hôtel-Dieu, Paris

来源：

PEDIATRIC NEPHROLOGY | 1992年 / 6卷 / 02期

关键词：

RENAL TRANSPLANT; RENAL INSUFFICIENCY; CYTOMEGALOVIRUS; GANCICLOVIR; PHARMACOKINETICS;

D O I：

10.1007/BF00866315

中图分类号：

R72 [儿科学];

学科分类号：

100202 ;

摘要：

Three cytomegalovirus (CMV)-seronegative children received renal transplants from CMV-seropositive donors and developed clinical symptoms of CMV infection between days 20 and 34 post transplantation. Ganciclovir (DHPG) was administered in a 1-h infusion, and the doses and dose intervals were adapted to the degree of renal insufficiency, according to the manufacturer's recommendations for adults. Individual pharmacokinetic parameters of DHPG were determined and were markedly altered. Plasma clearances were 0.4, 1.1 and 2.2 ml/min per kg and were related to individual creatinine clearances (20, 45 and 60 ml/min per 1.73 m2); the corresponding elimination half-lives were 23.7, 9.9 and 3.9 h. In two patients, the doses had to be further reduced in order to maintain plasma levels within the recommended values for peak and trough plasma concentrations. Therefore, monitoring of DHPG appears essential in adjusting dosage for optimal efficacy and minimal toxicity.

引用

页码：194 / 196

页数：3

共 15 条

[1]

Rubin R.H., Impact of cytomegalovirus infection on organ transplant recipients, Rev Infect Dis, 12, pp. S754-S766, (1990)

[2]

Laskin O.L., Cederberg D.M., Mills J., Eron L.J., Mildvan D., Spector S.A., Ganciclovir for the treatment and suppression of serious infections caused by cytomegalovirus, The American Journal of Medicine, 83, pp. 201-207, (1987)

[3]

Plotkin S.A., Drew W.L., Felsenstein D., Hirsch, Sensitivity of clinical isolates of human cytomegalovirus to 9-(1,3-dihydroxy-2-propoxymethyl)guanine, J Infect Dis, 152, pp. 833-839, (1985)

[4]

Fletcher C., Sawchuk R., Chinnock B., de Miranda P., Balfour H.H., Human pharmacokinetics of the antiviral drug DHPG, Clin Pharmacol Ther, 40, pp. 281-286, (1986)

[5]

Ho M., Epidemiology of cytomegalovirus infections, Rev Infect Dis, 12, pp. S701-S710, (1990)

[6]

Rubin R.H., Tolkoff-Rubin N.E., Oliver D., Rota T.R., Hamilton J., Betts R.F., Pass R.F., Hillis W., Szumuness W., Farrell M.L., Hirsch, Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation, Transplantation, 40, pp. 243-249, (1985)

[7]

Peterson P.K., Balfour H.H., Marker S.C., Fryd D.S., Howard R.J., Simmons R.L., Cytomegalovirus disease in renal allograft recipients: a prospective study of the clinical features, risk factors and impact on renal transplantation, Medicine (Baltimore), 59, pp. 283-300, (1980)

[8]

Dunn D.I., Mayoral J.L., Gillinghan K.J., Loeffler C.M., Brayman K.L., Kramer M.A., Erico A., Balfour H.H., Fletcher C.V., Bolman R., Matas A.J., Payne W.D., Sutherland D.E.R., Najarian J.S., Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir, Transplantation, 51, pp. 98-105, (1991)

[9]

Snydman D.R., Werner B.G., Heinze-Lacey B., Berardi V.P., Tilney N.L., Kirkman R.L., Milford E.L., Cho S.I., Bush H.L., Levey A.S., Strom T.B., Carpenter C.B., Levey R.H., Harmon W.E., Zimmerman C.E., Shapiro M.E., Steinman T., Logerfo F., Iselson B., Schroter, Levin M.J., McIver J., Leszczynski J., Grady G.F., Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal transplant recipients, N Engl J Med, 317, pp. 1049-1054, (1987)

[10]

Snydman D.R., Werner B.G., Tilney N.L., Kirkman R.I., Milford E.L., Cho S.I., Bush H.L., Levey A.S., Strom T.B., Carpenter C.B., Berardi V., Levey R., Harmon W.E., Zimmerman C.E., Tenny A., Heinze-Lacey B., Shapiro M.E., Steinman T., Logerfo F., Idelson B., McIver J., Leszczynski J., Grady G.F., A further analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus immune globulin: interim comparison of a randomized and open-label trial, Transplan

← 1 2 →